Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilar Deals 2025
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Helen Macpherson
Intranet
Kimberley Evans
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Approval alert: NMPA approves CTTQ’s DELITUO® biosimilar to Roche’s Mabthera® (rituximab)

May 30, 2023

Chia Tai Tianqing announced that it received a drug registration certificate from China’s National Medical Products Administration for DELITUO® biosimilar to Roche’s Mabthera® (rituximab). It is indicated for treatment of non-Hodgkin’s lymphoma (follicular lymphoma, CD20-positive diffuse large B-cell lymphoma, chronic lymphoma Tumor cell leukemia).

In March 2022, Henlius obtained NMPA approval of its rituximab biosimilar (汉利康®).